Ignite Creation Date:
2025-12-24 @ 4:44 PM
Ignite Modification Date:
2025-12-29 @ 2:09 AM
Study NCT ID:
NCT07215650
Status:
RECRUITING
Last Update Posted:
2025-11-17
First Post:
2025-09-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009157', 'term': 'Myasthenia Gravis'}], 'ancestors': [{'id': 'D020361', 'term': 'Paraneoplastic Syndromes, Nervous System'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D010257', 'term': 'Paraneoplastic Syndromes'}, {'id': 'D020274', 'term': 'Autoimmune Diseases of the Nervous System'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D020511', 'term': 'Neuromuscular Junction Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 44}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-09-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2028-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-13', 'studyFirstSubmitDate': '2025-09-24', 'studyFirstSubmitQcDate': '2025-10-02', 'lastUpdatePostDateStruct': {'date': '2025-11-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-10-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and severity of treatment-emergent adverse events through end of study', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in vital signs through end of study: body temperature', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in vital signs through end of study: heart rate', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in vital signs through end of study: respiratory rate', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in vital signs through end of study: blood pressure', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in vital signs through end of study: pulse oximetry', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in ECG parameters through end of study: PR interval', 'timeFrame': 'Baseline to Month12'}, {'measure': 'Changes from baseline in ECG parameters through end of study: QRS interval', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in ECG parameters through end of study: QTcF interval', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in safety laboratory assessments through end of study: serum chemistry', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Changes from baseline in safety laboratory assessments through end of study: hematology', 'timeFrame': 'Baseline to Month 12'}], 'secondaryOutcomes': [{'measure': 'Pharmacokinetic (PK) parameters for Cizutamig: Cmax', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'PK parameters for Cizutamig: time of maximum concentration', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'PK parameters for Cizutamig: area under the concentration-time curve', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'PK parameters for Cizutamig: clearance', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'PK parameters for Cizutamig: volume of distribution', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'PK parameters for Cizutamig: half-life', 'timeFrame': 'Baseline to Month 12'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Generalized Myasthenia Gravis']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.', 'detailedDescription': 'This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of cizutamig in patients with Generalized Myasthenia Gravis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. At least 18 years old at the time of signing the Informed Consent Form (ICF);\n2. Diagnosed with MG, classified as MGFA Class II-IVa, and judged by the investigator as unlikely to require respiratory support during the study;\n3. At screening, the Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 5, with non-ocular items accounting for ≥ 50% of the total score, and GMG ≥ 11;\n4. Inadequate response to conventional therapies or lack of effective treatment options, defined as disease recurrence or progression despite treatment with corticosteroids, immunosuppressants (e.g., azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, methotrexate), or biologics (e.g., rituximab), and/or lack of effective treatment methods.\n\nExclusion Criteria:\n\n1. Any history of CAR-T or TCE therapy targeting any antigen or BCMA-targeted therapy;\n2. Use of any approved immunosuppressive drugs not listed here within 12 weeks or 5 half-lives (whichever is longer) before screening, unless approved by the medical monitor;\n3. Participation in any investigational trial involving non-biological agents within 4 weeks or 5 half-lives (whichever is longer) of the investigational product (IP) before screening;\n4. Participation in any investigational trial involving biological agents within 12 weeks or 5 half-lives (whichever is longer) of the IP before screening;\n5. Administration of live vaccines within 4 weeks before screening;\n6. History of progressive multifocal leukoencephalopathy;\n7. History of primary immunodeficiency (e.g., hypogammaglobulinemia) or hereditary complement deficiency;\n8. Presence of one or more significant concurrent diseases, as judged by the investigator, including but not limited to:\n\n 1. Poorly controlled diabetes\n 2. Chronic kidney disease stages IIIb, IV, or V\n 3. Severe chronic pulmonary disease (e.g., requiring supplemental oxygen) or respiratory failure\n9. Any severe medical condition or clinically significant laboratory abnormality that, in the judgment of the investigator or medical monitor, would compromise the patient's safe participation and completion of the study or may affect protocol compliance or interpretation of study results."}, 'identificationModule': {'nctId': 'NCT07215650', 'briefTitle': 'Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Candid Therapeutics'}, 'officialTitle': 'A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Generalized Myasthenia Gravis (gMG)', 'orgStudyIdInfo': {'id': 'CND106-107'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cizutamig', 'interventionNames': ['Drug: Cizutamig']}], 'interventions': [{'name': 'Cizutamig', 'type': 'DRUG', 'otherNames': ['CND106'], 'description': 'Cizutamig will be dosed according to the protocol', 'armGroupLabels': ['Cizutamig']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Huashan Hospital Affiliated to Fudan University', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'xiao dai', 'role': 'CONTACT', 'email': 'xiao@candidrx.com', 'phone': '+8618521520014'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Candid Therapeutics', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}